Oliver Eickelberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Oliver Eickelberg has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Melanie Königshoff
University of Pittsburgh
19 shared publications Aö Yildirim
11 shared publications- Ali Önder Yildirim
Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
10 shared publications - Claudia A. Staab-Weijnitz
Comprehensive Pneumology Center with the CPC-M bioArchive and Institute of Lung Health and Immunity, Member of the German Center of Lung Research (DZL), Helmholtz-Zentrum München, Munich, Germany.
10 shared publications W. Seeger
10 shared publicationsJürgen Behr
Asklepios Fachkliniken München-Gauting, Munich, Germany
9 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (22)
AI policies for authors, reviewers, and editors at the JCI and JCI Insight
- 17 September 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (22)
Open AccessAI policies for authors, reviewers, and editors at the JCI and JCI Insight
- Open Access
- 8 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Turning the tide on organ fibrosis: a special issue on scientific advances and next-generation treatments
- 8 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Open AccessTurning the tide on organ fibrosis: a special issue on scientific advances and next-generation treatments
- Open Access
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Stabilizing and strengthening the US physician-scientist faculty workforce in academic medicine: a proposed institutional framework
Physician-scientists represent one of the most impactful, yet underrecognized, innovations of 20th century academic medicine. Defined by a commitment to full-time careers in investigative work, physician-scientists have repeatedly demonstrated a unique ability to identify and solve problems of unmet medical need in a focused and intentional manner using their dual training in clinical medicine and the scientific method as both stethoscope and scalpel. Unfortunately, while the value of physician-scientists has never been greater, the institutional infrastructure to support them has never been explicitly defined (1), a deficiency now amplified by mounting financial pressures from both clinical revenue models and an increasingly constrained research funding landscape (2, 3). This white paper reports the output of a consortium of academic medical centers, foundations, and professional societies seeking to remedy this deficiency. This consortium specifically developed a framework to formalize the career path of physician-scientist faculty into a professionally unified and financially sustainable structure amenable to adoption across US academic medical centers and health systems. Key components of this framework included an administratively operational definition of physician-scientists, and 3 central and interconnected pillars (academic, financial, and organizational) that are rooted in this foundational definition. Herein, we detail core concepts and concrete recommendations.
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Open AccessStabilizing and strengthening the US physician-scientist faculty workforce in academic medicine: a proposed institutional framework
Physician-scientists represent one of the most impactful, yet underrecognized, innovations of 20th century academic medicine. Defined by a commitment to full-time careers in investigative work, physician-scientists have repeatedly demonstrated a unique ability to identify and solve problems of unmet medical need in a focused and intentional manner using their dual training in clinical medicine and the scientific method as both stethoscope and scalpel. Unfortunately, while the value of physician-scientists has never been greater, the institutional infrastructure to support them has never been explicitly defined (1), a deficiency now amplified by mounting financial pressures from both clinical revenue models and an increasingly constrained research funding landscape (2, 3). This white paper reports the output of a consortium of academic medical centers, foundations, and professional societies seeking to remedy this deficiency. This consortium specifically developed a framework to formalize the career path of physician-scientist faculty into a professionally unified and financially sustainable structure amenable to adoption across US academic medical centers and health systems. Key components of this framework included an administratively operational definition of physician-scientists, and 3 central and interconnected pillars (academic, financial, and organizational) that are rooted in this foundational definition. Herein, we detail core concepts and concrete recommendations.
- Open Access
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis
Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell–specific Gdf15 -KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15 -deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca 2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca 2+ signaling and a contributor to lung injury and fibrosis.
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Open AccessEndothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis
Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell–specific Gdf15 -KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15 -deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca 2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca 2+ signaling and a contributor to lung injury and fibrosis.
- Open Access
- 10 April 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (10) , 3589-3638
SenSet defines cell-type specific senescence signatures in the aged human lung
Cellular senescence is defined as an irreversible growth arrest observed when cells are exposed to a variety of stressors, including DNA damage, oxidative stress, or nutrient deprivation. Although senescence is a well-established driver of aging and age-related diseases, it is a highly heterogeneous process with significant variations across organisms, tissues, and cell types. The relatively low abundance of senescent cells in healthy aged tissues poses a major challenge to the longitudinal study of senescence in specific organs, including the human lung. To overcome this limitation, we developed a positive-unlabeled learning framework to generate a comprehensive list of senescence marker genes in human lungs (termed SenSet) using the largest publicly available single-cell lung dataset, the Human Lung Cell Atlas (HLCA). We validated SenSet in a highly complex ex vivo human 3D lung tissue culture model subjected to the senescence inducers bleomycin, doxorubicin, or irradiation, and established its sensitivity and accuracy in characterizing senescence. Using SenSet, we identified and validated cell-type-specific senescence signatures in distinct lung cell populations upon aging and environmental exposure. Our study provides a comprehensive analysis of senescent cells in the healthy aging lung, presenting fundamental implications for our understanding of major lung diseases, including cancer, fibrosis, chronic obstructive pulmonary disease, or asthma.
- 10 April 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (10) , 3589-3638
Open AccessSenSet defines cell-type specific senescence signatures in the aged human lung
Cellular senescence is defined as an irreversible growth arrest observed when cells are exposed to a variety of stressors, including DNA damage, oxidative stress, or nutrient deprivation. Although senescence is a well-established driver of aging and age-related diseases, it is a highly heterogeneous process with significant variations across organisms, tissues, and cell types. The relatively low abundance of senescent cells in healthy aged tissues poses a major challenge to the longitudinal study of senescence in specific organs, including the human lung. To overcome this limitation, we developed a positive-unlabeled learning framework to generate a comprehensive list of senescence marker genes in human lungs (termed SenSet) using the largest publicly available single-cell lung dataset, the Human Lung Cell Atlas (HLCA). We validated SenSet in a highly complex ex vivo human 3D lung tissue culture model subjected to the senescence inducers bleomycin, doxorubicin, or irradiation, and established its sensitivity and accuracy in characterizing senescence. Using SenSet, we identified and validated cell-type-specific senescence signatures in distinct lung cell populations upon aging and environmental exposure. Our study provides a comprehensive analysis of senescent cells in the healthy aging lung, presenting fundamental implications for our understanding of major lung diseases, including cancer, fibrosis, chronic obstructive pulmonary disease, or asthma.
- Open Access
- 9 January 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (1)
Prepare for slingshot
There are few aspects of my profession that I enjoy as much as reading, evaluating, and discussing primary research papers. Hence, I was honored and excited to assume the role of Editor in Chief of JCI Insight in September 2024. With only slightly more than 15 months on the job, it is my honor and pleasure to contribute this Editorial for the ten-year anniversary of JCI Insight. It is safe to say that, as a journal, we are now entering adolescence. I prepared this Editorial as we were celebrating the Thanksgiving holiday, so bear with me as I express my sincere gratitude for the past 15 months at JCI Insight to the following people: First and foremost, to Corinne Williams, our Senior Science Editor, without whom this Journal would hardly thrive. Second, to Sarah Jackson, Executive Editor of the JCI Family of Journals, who masterfully coordinates and oversees all publishing activities. Third, to our wonderful and expert team of Deputy and Associate Editors at the University of Pittsburgh-Yinz rock! Fourth, to the ASCI, its leadership, and JCI Insight Founding Editor Howard Rockman for delivering on the bold vision to establish JCI Insight as a sister journal to the Journal of Clinical Investigation (JCI) back in 2016. What a courageous feat to lead two journals that are self-published by the ASCI and establish the founding vision for this Journal by publishing "preclinical, translational, and clinical research that uncovers new insights into the basis of disease and therapeutic approaches" (1). To Kathleen Collins, the immediate past JCI Insight Editor in Chief, and her team at the University of Michigan, for steering the Journal through the COVID-19 pandemic and establishing a range of new initiatives, particularly the Physician-Scientist Development section. To Elizabeth McNally and the entire JCI editorial team at Northwestern University for providing invaluable insight and partnership for JCI Insight submissions coming from the Dual-Journal Submission track or as transfers from the JCI. To my institution and its leadership, in particular Dean Anantha Shekhar and Chair of Medicine Anne Marie Lennon, for generously supporting the Editorial Board and me for this tenure. These are rocky times for institutional support mechanisms for scientific ventures like this; hence, your support is even more appreciated. And finally, to our academic community-of authors, reviewers, and readers-who donate precious time and insight for a service so essential to the mission of our academic institutions to better understand, detect, prevent, and cure disease. Here we are, a decade later, with over 4,500 articles published and more than 150,000 citations, and a reader-and authorship that spans almost every continent. So where do we steer our spacecraft from here over the next years? Our current University of Pittsburgh-based team onboarded about a year ago with the mission "Go, Flight," trusting in successful liftoff (2). I would argue that we have successfully launched and established cruising altitude and speed for steady space flight, avoiding asteroid debris where possible. We now aim for our first slingshot maneuver acceleration soon. In the cargo bay of our spacecraft, we have successfully loaded several new initiatives, including the recently established DualJournal Submission track in collaboration with the JCI; thematic Journal issues (the first of which is on cross-organ fibrosis, to be published mid-2026), an expanded Physician-Scientist Development section; regularly featured state-of-theart reviews; onboarding of early-stage investigators (ASCI/Young Physician Scientist Award [YPSA] and Emerging-Generation [E-Gen] Award recipients) to the Editorial Board; and inclusion of YPSA awardees in our guaranteed external review program. JCI Insight is proud to support physician-scientists throughout all stages of their career, with an emphasis on those in the early stages. As we look to the next decade of JCI Insight, we will continuously aim to improve upon aspects of scientific publishing that we can and should do better on. The peer review process remains under scrutiny. Our scientific community, as well as the general public, questions whether peer review will and should remain the gold-standard process to evaluate scientific findings. Many question whether we should abandon this laborious and time-consuming process and instead rapidly publish all scientific literature on freely accessible servers for everyone, without peer-review or editorial processing. I would argue that we absolutely need to maintain and protect free and open access of federally funded (i.e., taxpayer-supported) biomedical research, a process fully supported at the JCI and JCI Insight. I would also argue, however, against abandoning peer review entirely and switching to postpublication discussions and evaluations instead. For example, during the initial months of the COVID-19 pandemic, non-peer-reviewed preprint publications were rapidly disseminated and expeditiously amplified by media outlets, which undoubtedly led to confusing and harmful consequences and ethically questionable actions for our patients. This is only one but an important advantage of the peer review publication process.
- 9 January 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (1)
Open AccessPrepare for slingshot
There are few aspects of my profession that I enjoy as much as reading, evaluating, and discussing primary research papers. Hence, I was honored and excited to assume the role of Editor in Chief of JCI Insight in September 2024. With only slightly more than 15 months on the job, it is my honor and pleasure to contribute this Editorial for the ten-year anniversary of JCI Insight. It is safe to say that, as a journal, we are now entering adolescence. I prepared this Editorial as we were celebrating the Thanksgiving holiday, so bear with me as I express my sincere gratitude for the past 15 months at JCI Insight to the following people: First and foremost, to Corinne Williams, our Senior Science Editor, without whom this Journal would hardly thrive. Second, to Sarah Jackson, Executive Editor of the JCI Family of Journals, who masterfully coordinates and oversees all publishing activities. Third, to our wonderful and expert team of Deputy and Associate Editors at the University of Pittsburgh-Yinz rock! Fourth, to the ASCI, its leadership, and JCI Insight Founding Editor Howard Rockman for delivering on the bold vision to establish JCI Insight as a sister journal to the Journal of Clinical Investigation (JCI) back in 2016. What a courageous feat to lead two journals that are self-published by the ASCI and establish the founding vision for this Journal by publishing "preclinical, translational, and clinical research that uncovers new insights into the basis of disease and therapeutic approaches" (1). To Kathleen Collins, the immediate past JCI Insight Editor in Chief, and her team at the University of Michigan, for steering the Journal through the COVID-19 pandemic and establishing a range of new initiatives, particularly the Physician-Scientist Development section. To Elizabeth McNally and the entire JCI editorial team at Northwestern University for providing invaluable insight and partnership for JCI Insight submissions coming from the Dual-Journal Submission track or as transfers from the JCI. To my institution and its leadership, in particular Dean Anantha Shekhar and Chair of Medicine Anne Marie Lennon, for generously supporting the Editorial Board and me for this tenure. These are rocky times for institutional support mechanisms for scientific ventures like this; hence, your support is even more appreciated. And finally, to our academic community-of authors, reviewers, and readers-who donate precious time and insight for a service so essential to the mission of our academic institutions to better understand, detect, prevent, and cure disease. Here we are, a decade later, with over 4,500 articles published and more than 150,000 citations, and a reader-and authorship that spans almost every continent. So where do we steer our spacecraft from here over the next years? Our current University of Pittsburgh-based team onboarded about a year ago with the mission "Go, Flight," trusting in successful liftoff (2). I would argue that we have successfully launched and established cruising altitude and speed for steady space flight, avoiding asteroid debris where possible. We now aim for our first slingshot maneuver acceleration soon. In the cargo bay of our spacecraft, we have successfully loaded several new initiatives, including the recently established DualJournal Submission track in collaboration with the JCI; thematic Journal issues (the first of which is on cross-organ fibrosis, to be published mid-2026), an expanded Physician-Scientist Development section; regularly featured state-of-theart reviews; onboarding of early-stage investigators (ASCI/Young Physician Scientist Award [YPSA] and Emerging-Generation [E-Gen] Award recipients) to the Editorial Board; and inclusion of YPSA awardees in our guaranteed external review program. JCI Insight is proud to support physician-scientists throughout all stages of their career, with an emphasis on those in the early stages. As we look to the next decade of JCI Insight, we will continuously aim to improve upon aspects of scientific publishing that we can and should do better on. The peer review process remains under scrutiny. Our scientific community, as well as the general public, questions whether peer review will and should remain the gold-standard process to evaluate scientific findings. Many question whether we should abandon this laborious and time-consuming process and instead rapidly publish all scientific literature on freely accessible servers for everyone, without peer-review or editorial processing. I would argue that we absolutely need to maintain and protect free and open access of federally funded (i.e., taxpayer-supported) biomedical research, a process fully supported at the JCI and JCI Insight. I would also argue, however, against abandoning peer review entirely and switching to postpublication discussions and evaluations instead. For example, during the initial months of the COVID-19 pandemic, non-peer-reviewed preprint publications were rapidly disseminated and expeditiously amplified by media outlets, which undoubtedly led to confusing and harmful consequences and ethically questionable actions for our patients. This is only one but an important advantage of the peer review publication process.
- Open Access
- 25 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
An open letter to the NIH: value and costs in publishing
- 25 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Open AccessAn open letter to the NIH: value and costs in publishing
- Open Access
- 28 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (21)
Publishing gold standard science
- 28 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (21)
Open AccessPublishing gold standard science
- Top Cited PapersOpen Access
- 2 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease characterized by excessive extracellular matrix deposition. Current IPF therapies slow disease progression but do not stop or reverse it. The (myo)fibroblasts are thought to be the main cellular contributors to excessive extracellular matrix production in IPF. Here we show that fibrotic alveolar type II cells regulate production and crosslinking of extracellular matrix via the co-transcriptional activator YAP. YAP leads to increased expression of Lysl oxidase (LOX) and subsequent LOX-mediated crosslinking by fibrotic alveolar type II cells. Pharmacological YAP inhibition via verteporfin reverses fibrotic alveolar type II cell reprogramming and LOX expression in experimental lung fibrosis in vivo and in human fibrotic tissue ex vivo. We thus identify YAP-TEAD/LOX inhibition in alveolar type II cells as a promising potential therapy for IPF patients.
- 2 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Top Cited PapersOpen AccessInhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease characterized by excessive extracellular matrix deposition. Current IPF therapies slow disease progression but do not stop or reverse it. The (myo)fibroblasts are thought to be the main cellular contributors to excessive extracellular matrix production in IPF. Here we show that fibrotic alveolar type II cells regulate production and crosslinking of extracellular matrix via the co-transcriptional activator YAP. YAP leads to increased expression of Lysl oxidase (LOX) and subsequent LOX-mediated crosslinking by fibrotic alveolar type II cells. Pharmacological YAP inhibition via verteporfin reverses fibrotic alveolar type II cell reprogramming and LOX expression in experimental lung fibrosis in vivo and in human fibrotic tissue ex vivo. We thus identify YAP-TEAD/LOX inhibition in alveolar type II cells as a promising potential therapy for IPF patients.
- Open Access
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eads1532
Dietary methionine restriction started late in life promotes healthy aging in a sex-specific manner
Aging is associated with dysregulated methionine metabolism and increased levels of enzymes in the tyrosine degradation pathway (TDP). To investigate the efficacy of targeting either methionine metabolism or the TDP for healthspan improvement in advanced age, we initiated dietary MetR or TDP inhibition in 18-month-old C57BL/6J mice. MetR significantly improved neuromuscular function, metabolic health, lung function, and frailty. In addition, we confirmed improved neuromuscular function from dietary MetR in 5XFAD mice, whose weight was not affected by MetR. We did not observe benefits with TDP inhibition. Single-nucleus RNA and ATAC sequencing of muscle revealed cell type–specific responses to MetR, although MetR did not significantly affect mouse aging epigenetic clock markers. Similarly, an 8-week MetR intervention in a human trial (NCT04701346) showed no significant impact on epigenetic clocks. The observed benefits from late-life MetR provide translational rationale to develop MetR mimetics as an antiaging intervention.
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eads1532
Open AccessDietary methionine restriction started late in life promotes healthy aging in a sex-specific manner
Aging is associated with dysregulated methionine metabolism and increased levels of enzymes in the tyrosine degradation pathway (TDP). To investigate the efficacy of targeting either methionine metabolism or the TDP for healthspan improvement in advanced age, we initiated dietary MetR or TDP inhibition in 18-month-old C57BL/6J mice. MetR significantly improved neuromuscular function, metabolic health, lung function, and frailty. In addition, we confirmed improved neuromuscular function from dietary MetR in 5XFAD mice, whose weight was not affected by MetR. We did not observe benefits with TDP inhibition. Single-nucleus RNA and ATAC sequencing of muscle revealed cell type–specific responses to MetR, although MetR did not significantly affect mouse aging epigenetic clock markers. Similarly, an 8-week MetR intervention in a human trial (NCT04701346) showed no significant impact on epigenetic clocks. The observed benefits from late-life MetR provide translational rationale to develop MetR mimetics as an antiaging intervention.